Study published in EClinicalMedicine confirms safety and immunogenity of world’s first Needle-free COVID-19 DNA vaccine
Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response. Delivery by PharmaJet Tropis induced cellular expression that reached higher values (2.69 x 109 +/- 1.57 x 109 p/s/cm2/sr) than electroporation delivery (1.3 x108 +/- 1.46 x107).
The porcine reproductive and respiratory syndrome virus (PRRSV), an RNA virus that induces respiratory disease in young pigs is a leading cause of economic loss in the industry. Modified live vaccines help control the disease but their efficacy is often compromised by high genetic diversity. While electroporation has been shown to be effective, it is not ideal for vaccine delivery in field conditions. Furthermore, there are significant concerns regarding pain and ease of delivery with electroporation. The Tropis Needle-free Injection System is a simple delivery system that can easily be adapted for veterinary use and has been shown to be particularly efficient in induction of high neutralizing antibody responses in pigs using DNA encoding influenza antigens.
To learn more, please refer to the full study, which was published in Viruses on June 25, 2019.
Related posts
